Aaron Davis, MD
Allergy & Immunology · Scottsdale, AZNPI 1861477739
Payments from drug & device makers
Across 172 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$735
- Pfizer$284
- Sanofi$258
- Novartis$251
- Biocryst US Sales Co., LLC$194
- CSL Behring$173
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,083100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 51 | $735 |
| Pfizer | 16 | $284 |
| Sanofi | 13 | $258 |
| Novartis | 14 | $251 |
| Biocryst US Sales Co., LLC | 9 | $194 |
| CSL Behring | 7 | $173 |
| Pharming Healthcare, Inc. | 8 | $164 |
| AstraZeneca | 9 | $144 |
| Regeneron Healthcare Solutions, Inc. | 6 | $135 |
| Optinose US, Inc. | 7 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $108 |
| Shire North American Group Inc | 5 | $86 |
| Genentech USA, Inc. | 3 | $62 |
| Boehringer Ingelheim | 2 | $61 |
| Grifols USA, LLC | 3 | $49 |
| Kaleo, Inc. | 2 | $48 |
| Octapharma USA, Inc. | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Blueprint Medicines Corporation | 1 | $22 |
| Incyte Corporation | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Biocryst Pharmaceuticals, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $18 |
| Viatris Specialty LLC | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
How this compares
$3,083 in reported general payments places this provider in the 50th percentile of 90 allergy & immunology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 67 | $351,910 |
| Dupixent SyringeDupilumab | 46 | $222,926 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $81,324 |
| Breo ElliptaFluticasone/Vilanterol | 116 | $72,482 |
| XolairOmalizumab | 23 | $68,901 |
| Advair HfaFluticasone Propion/Salmeterol | 67 | $30,817 |
| SymbicortBudesonide/Formoterol Fumarate | 67 | $30,447 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $24,545 |
| Spiriva RespimatTiotropium Bromide | 29 | $21,538 |
| DuleraMometasone/Formoterol | 21 | $16,081 |
| Arnuity ElliptaFluticasone Furoate | 37 | $15,123 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $12,314 |
| Advair DiskusFluticasone Propion/Salmeterol | 25 | $12,025 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 53 | $10,548 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 209 | $8,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $173 | $351,91067 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $735 | $168,929235 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $144 | $54,99284 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $61 | $33,85245 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $30 | $1,77912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 90 allergy & immunology providers in Arizona.
Other allergy & immunology in Scottsdale
- Michael ManningScottsdale$3.2M
- Jennifer HillScottsdale$418K
- Jean NelsonScottsdale$183K
- Kiranjit KhalsaScottsdale$150K
- Sanjay PatelScottsdale$21K
- Hiral ThakrarScottsdale$19K
- Rachael StillwagonScottsdale$7K
- Rebecca KoenigsbergScottsdale$3K
- Matthew RankScottsdale$1K
- Connie HsuLitchfield Park$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.